Related Experiment Video
Updated: Mar 15, 2026

Cell Population Analyses During Skin Carcinogenesis
Published on: August 21, 2013
Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma
Patrizia Cammareri1, Aidan M Rose2, David F Vincent1
1Wnt Signaling and Colorectal Cancer Group, Cancer Research UK Beatson Institute, Institute of Cancer Sciences, Glasgow University, Garscube Estate, Switichback Road, Glasgow G61 1BD, UK.
Abstract:
Melanoma patients treated with oncogenic BRAF inhibitors can develop cutaneous squamous cell carcinoma (cSCC) within weeks of treatment, driven by paradoxical RAS/RAF/MAPK pathway activation. Here we identify frequent TGFBR1 and TGFBR2 mutations in human vemurafenib-induced skin lesions and in sporadic cSCC. Functional analysis reveals these mutations ablate canonical TGFβ Smad signalling, which is localized to bulge stem cells in both normal human and murine skin. MAPK pathway hyperactivation (through Braf(V600E) or Kras(G12D) knockin) and TGFβ signalling ablation (through Tgfbr1 deletion) in LGR5(+ve) stem cells enables rapid cSCC development in the mouse. Mutation of Tp53 (which is commonly mutated in sporadic cSCC) coupled with Tgfbr1 deletion in LGR5(+ve) cells also results in cSCC development. These findings indicate that LGR5(+ve) stem cells may act as cells of origin for cSCC, and that RAS/RAF/MAPK pathway hyperactivation or Tp53 mutation, coupled with loss of TGFβ signalling, are driving events of skin tumorigenesis.
Insights
Oncogenic BRAF inhibitor treatment can cause skin cancer (cSCC) due to pathway activation. Mutations in TGFBR1/2 and loss of TGFβ signaling in stem cells drive cSCC development, indicating these stem cells are key to skin tumorigenesis.
Area of Science:
- Dermatology
- Oncology
- Molecular Biology
Background:
- Melanoma patients on BRAF inhibitors can develop cutaneous squamous cell carcinoma (cSCC).
- This is driven by paradoxical RAS/RAF/MAPK pathway activation.
- TGFβ signaling plays a role in skin homeostasis.
Purpose of the Study:
- To identify genetic drivers of vemurafenib-induced cSCC.
- To investigate the role of TGFβ signaling in skin stem cells in cSCC development.
- To explore the cell of origin for cSCC.
Main Methods:
- Analysis of human vemurafenib-induced skin lesions and sporadic cSCC for mutations.
- Functional studies of TGFβ signaling in mouse models.
- Genetic manipulation of stem cells (LGR5+ve) in mice.
Main Results:
- Frequent TGFBR1 and TGFBR2 mutations were found in human cSCC lesions.
- These mutations ablate canonical TGFβ Smad signaling.
- Combined MAPK hyperactivation or Tp53 mutation with TGFβ signaling loss in LGR5+ve stem cells rapidly induced cSCC in mice.
Conclusions:
- LGR5+ve stem cells are identified as potential cells of origin for cSCC.
- Aberrant RAS/RAF/MAPK pathway activation or Tp53 mutation, alongside TGFβ signaling loss, are critical events in skin tumorigenesis.
More Related Videos
Related Concept Videos
TGF - β Signaling Pathway
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Induced Pluripotent Stem Cells
Somatic...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)